Who Owns Maze Therapeutics Stock?
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 106.88%
- Institutions (% of float)
- 108.54%
- Held by insiders
- 1.53%
- Institutional holders
- 228
- Institutions 98.5%
- Insiders 1.5%
- Public and other 0.0%
Who owns Maze Therapeutics stock?
Institutional investors own about 106.9% of Maze Therapeutics's shares, spread across 228 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 1.53% of MAZE.
The largest institutional holders are Frazier Life Sciences Management, L.P. (9.06%), TRV GP IV, LLC (8.05%) and Arch Venture Management, Llc (7.42%). Together, the top 10 institutions control 58.1% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their MAZE positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of MAZE
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5.03M | 9.06% | +10.2% |
| TRV GP IV, LLC | 4.47M | 8.05% | 0.0% |
| Arch Venture Management, Llc | 4.12M | 7.42% | 0.0% |
| Deep Track Capital, Lp | 3.73M | 6.72% | +7.3% |
| Blackrock Inc. | 3.50M | 6.31% | +36.3% |
| Jupiter Topco LLC | 3.41M | 6.14% | +100.0% |
| T. Rowe Price Investment Management, Inc. | 2.60M | 4.69% | +100.0% |
| Logos Global Management LP | 1.94M | 3.48% | +56.7% |
| Vanguard Capital Management LLC | 1.78M | 3.20% | +23.9% |
| a16z Capital Management, L.L.C. | 1.70M | 3.06% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of MAZE
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.41M | 2.54% |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 978.33K | 1.76% |
| iShares Trust-iShares Russell 2000 ETF | 906.42K | 1.63% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 787.46K | 1.42% |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 421.35K | 0.76% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 385.64K | 0.69% |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | 362.13K | 0.65% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 325.51K | 0.59% |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 295.46K | 0.53% |
| iShares Trust-iShares Russell 2000 Growth ETF | 278.19K | 0.50% |
Frequently asked questions
Who is the largest shareholder of Maze Therapeutics?
Frazier Life Sciences Management, L.P. is the largest institutional shareholder of MAZE, owning 9.06% of shares outstanding (5.03M shares) as of its latest 13F filing.
What percentage of Maze Therapeutics is owned by institutions?
Institutions own about 106.9% of MAZE shares and 108.5% of the public float.
How much of Maze Therapeutics do insiders own?
Insiders, such as officers and directors, own about 1.53% of MAZE shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.